CARLA DARUICH DE SOUZA

CARLA DARUICH DE SOUZA

(Fonte: Lattes)

Resumo

Bsc in Medical Physics from UNESP in Botucatu Compleated at IPEN, University of São Paulo: 1) Master's Degree: Comparison between methods for fixing iodine-125 on silver substrate for fabricating sources used in Brachytherapy / 2) PhD: Parameters for production of iodine-125 sources used in brachytherapy and "sandwich" doctorate: Washington State University - training in radiochemistry and organic chemistry / 3) Post doctorate: Production of nanosources for the treatment of cancer / 4) Project: Analysis of methods to obtain / produce nuclear material for use in a radioisotope thermoelectric generator (RTG)/ Advisor of the Professional Master's Degree in Radiation Technology in Health / Professor of the Professional Master Program in the disciplines Dosimetry for Radiotherapy and Radiotherapy Fundamentals / Professor of the Academic Master Program in the discipline TNA5805 - Brachytherapy: Fundamentals, Production, Application, Dosimetry and Quality Research Associate of KAERI - Korean Atomic Energy and Research Institute (Text obtained from the Currículo Lattes on October 6th 2021)

Formada em Física Médica pela UNESP em Botucatu Realizado no IPEN-USP/ SP: 1) Mestrado: Comparação entre métodos de fixação do iodo-125 em substrato de prata para confecção de fontes utilizadas em Braquiterapia / 2) Doutorado: Parâmetros para produção de confecção de fontes de iodo-125 utilizadas em Braquiterapia e Doutorado sanduíche: Washington State University - treinamento em radioquímica / 3) Pós doutorado: Produção de nanofontes para tratamento de câncer / 4) Projeto: Análise de formas de obtenção/produção do material nuclear para utilização em um gerador termoelétrico radioisotópico (RTG)/ Orientadora do Mestrado Profissional de Tecnologia das Radiações na Saúde/ Professora do Mestrado Profissional nas disciplinas Dosimetria para Radioterapia e Fundamentos de Radioterapia/ Professora do Mestrado Acadêmico na disciplina TNA5805 - Braquiterapia: Fundamentos, Produção, Aplicação, Dosimetria e Qualidade Research Associate do KAERI - Korean Atomic Energy and Research Institute (Texto extraído do Currículo Lattes em 06 out. 2021)

Página do item completo

Resultados de Busca

Agora exibindo 1 - 10 de 68

Production of iodine-125 in nuclear reactors
2011 - ZEITUNI, CARLOS A.; ROSTELATO, MARIA E.C.M.; JAE-SON, KWANG; LEE, JUN S.; COSTA, OSVALDO L.; MOURA, JOÃO A.; FEHER, ANSELMO; MOURA, EDUARDO S.; SOUZA, CARLA D.; MATTOS, FABIO R.; PELEIAS JUNIOR, FERNANDO S.; KARAM JUNIOR, DIB
Cancer is one of the worst illnesses in the world and one of the major causes of death in Brazil [1,2]. For this reason, the Nuclear Energy National Commission (CNEN) started a project to produce some medical radioisotopes to treat cancer. One of the main products is the iodine-125 seeds [3]. This iodine seed can be used to treat several kinds of cancer: prostate, lung, eye, brain. As Brazil will construct a new reactor to produce radioisotopes, it is necessary define how the iodine-125 production will carry out [4,5]. The main reaction of this production is the irradiation of the enriched xenon-124 in gaseous form. Xe-124 changed to Iodine-125 by neutron capture following in two decays: Xe-124 (n, y) —• Xe-125m (57s) —• I- 125 or Xe-124 (n, y) —• Xe-125 (19.9 h) —• 1-125. However the production in reactors is the most common technique used, there is one disadvantage to use it: the production of iodine- 126 after several hours of irradiation. Iodine-126 has a half life of 13.1 days and it has some usefulness emitters for medical uses. Iodine-126 is considered a contamination [6]. For all these reasons, the IPEN/CNEN-SP research group decided for two techniques of production: in batch or continuous system. The production in batch consists in a sealed capsule that is placed in the reactor core for around 64 hours. In this type of production, some iodine-126 is produced and a certain quantity of Xe-124 is not activated. Normally, it needs to wait around 5 to 7 iodine-126 half-lives to guarantee the decrease of the activity of the contamination. This time will make Iodine-125 with only 50% till 34% of the initial production. The second technique is the continuous production using a cryogenic system. This technique consists in two capsules: one inside the reactor core and the second one out of the neutron flux. These two capsules will be linked with two cryogenic pumps to guarantee that all iodine-125 produced in the core will be take off the reactor core. The great disadvantage of this technique is the using of two positions in the core of the reactor. Brazil will have only one radioisotope reactor producing. And like there is a huge quantity of materials to be produced, it is not a guarantee the position in the reactor for this production. Besides of that the seeds production in Brazil is only 3000 per month, which demands around 3.5 Ci per month. The batch production produces a low quantity per reactor cycle of iodine-125, but this low quantity can be more than that [2,3].
Preliminary proposal for radioactive liquid waste management in a brachytherapy sources production laboratory
2011 - SOUZA, CARLA D.; VICENTE, ROBERTO; ROSTELATO, MARIA E.C.M.; ZEITUNI, CARLOS A.; MOURA, JOÃO A.; MOURA, EDUARDO S.; MATTOS, FABIO R.; FEHER, ANSELMO; COSTA, OSVALDO L. da; VIANNA, ESTANISLAU B.; CARVALHO, LAERCIO de; KARAN JUNIOR, DIB
Malignant tumors are responsible for a high death rate in the entire world population (1). Prostate cancer is the third most common among men, after skin and lung. The treatment using permanent Iodine-125 seed are too costly, preventing the use in large scale (1) (2). A multidisciplinary team was formed to develop a source of Iodine-125 and assemble a national facility for local production. For the production correct implementation, a plan for radiological protection that has the management of radioactive waste fully specified are necessary. This work has developed an initial liquid waste management proposal. The most important Iodine-125 liquid waste is generated in the first phase of the process, radioactive material fixation. The initial proposal is that the waste is deposited in a 20 L container (2 years to fill). The final activity of this container is 4.93 x 1011 Bq. According to the discharge limits presented in the brazilian's regulation CNEN - NE - 605 - Management of radioactive wastes in radioactive facilities (3) this waste could safely be release to the environment in 3.97 years. In the other hand,if a minimization waste policy will be implemented, the production could becomes more efficient and cheaper. Waste storage at 25 L containers and changing some production parameters results in 3 years waste to be eliminated in 3.94 years. This new plan will optimize the materials used and diminished the waste generation facilitating the management, contributing to a cheaper product.
Iridium-192 seed development for ophthalmic cancer treatment
2011 - ROSTELATO, M.E.C.M.; MATTOS, F.R.; ZEITUNI, C.A.; SOUZA, C.D.; MOURA, J.A.; MOURA, E.S.; FEHER, A.; COSTA, O.L.; PELEIAS JUNIOR, F.S.; MARQUES, J.R.O.; BELFORT NETO, R.
Considered a public health problem in Brazil, cancer is the second leading cause of mortality by disease, representing 13.2% of all deaths in the country [1]. Ophthalmic brachytherapy involves inserting an acrylic plate with radioactive material in the eyes of a patient for treatment of ocular tumors. This work is a partnership between Escola Paulista de Medicina - UNIFESP and the Instituto de Pesquisas Energéticas e Nucleares - IPEN for development and implementation of a cheaper therapeutic treatment for ophthalmic cancer with a iridium-192 source, to attend a greater number of patients. Iridium-192 is produced in nuclear reactor. It has a half-life of 74.2 days and decays by beta emission with average energy of 370 keV.[2,3]. The seed will be a platinum-iridium alloy core (80/20), encapsulated in a titanium tube [4]. This project will be divided into the following steps: characterization of materials by FRX (X-ray fluorescence) e EDS (Energy Dispersive Spectroscopy); iridium irradiation in the nuclear reactor IEA-R1; sealing of iridium-192 seed; leakage tests of iridium-192 source in accordance with standard ISO-9978 (radiation protection- Sealed radioactive sources- Leakage test methods) [5]; metallographic tests and measure the activity of the source. The evaluation for use in the ophthalmic treatment of cancer will be made later.
Improvements in the quality control of iridium-192 wire used in brachytherapy
2011 - COSTA, OSVALDO L.; ZEITUNI, CARLOS A.; ROSTELATO, MARIA E.C.M.; MOURA, JOÃO A.; FEHER, ANSELMO; MOURA, EDUARDO S.; SOUZA, CARLA D.; SOMESSARI, SAMIR L.
Brachytherapy is a method used in the treatment of cancerous tumors by ionizing radiation produced by sources introduced into the tumor area, this method seeks a more direct attack to the tumor, thereby maximizing the radiation dose to diseased tissue while minimizing the dose to healthy tissues (1). One of the radionuclides used in brachytherapy is iridium-192. The Radiation Technology Center (CTR) of the Nuclear and Energy Research Institute (IPEN) has produced commercially, since 1998, iridium-192 wires used in low dose rate (LDR) brachytherapy (2). To produce this radionuclide, firstly a iridium-platinum wire is irradiated in the nuclear reactor IEA-R1 for 30 hours with a neutron flux of 5 x 1013 ncm-2s-1, the wire is left to decay by 30 days to remove the main contaminants and then goes through a quality control before being sent to the hospital. In this quality control is checked the radiation homogeneity along each centimeter of the wire (3). To implement this procedure is used a device consisting of an ionization chamber surrounded by a lead shield with a small 1 cm wide slit, linked to the ionization chamber is a voltage source and a Keithley 617 electrometer, 2 minutes is the range used to measure the charge by the electrometer. The iridium wire is considered in accordance when there is no variation greater than 5% between the average measures and the maximum and minimum values. However, due to design features of the measurement system, the wire may appear to the detector through the slit in larger sizes than the ideal, improperly influencing the final quality control. This paper calculates the difference in size of these variations in profile and their influence on the final count, it compares the actual values obtained and describes the improvements made in quality control procedures that provided more accurate measurement data, analyzes the results and suggests changes in devices aimed at further improving the quality control of iridium-192 wires produced at IPEN and used in hospitals in Brazil.
Waste management protocols for Iridium-192 sources production laboratory used in cancer treatment
2016 - ROSTELATO, MARIA E.C.M.; SOUZA, CARLA D. de; SOUZA, DAIANE C.B. de; ZEITUNI, CARLOS A.; TIEZZI, RODRIGO; COSTA, OSVALDO L. da; RODRIGUES, BRUNA T.; MOURA, JOÃO A.; FEHER, ANSELMO; SORGATTI, ANDERSON; MOURA, EDUARDO S. de; MARQUES, JOSE R. de O.; SANTOS, RAFAEL M. dos; KARAM JUNIOR, DIB
Introduction: Brachytherapy is a form of treatment that uses radioactive seeds placed in contact or inside the region to be treated, maximizing the radiation dose inside the targeted areas. Iridium-192 is being used in brachytherapy since 1955. It presents emission energy in the “therapy region” (370keV) and is easily produced in a nuclear reactor (191Ir (n, γ) → 192Ir). Wires are an iridium-platinum alloy with 0.36 mm diameter and they can be cut in any needed length. They can be used in several types of cancer. The linear activity is between 1 mCi/cm (37 MBq/cm) and 4 mCi/cm (148 MBq/cm) with variations of 10% in 50 cm maximum. This activity values classified the treatment and low dose rate (0,4 à 2 Gy/h). The propose of this work is to present a waste management system in a cancer treatment radioactive sources production laboratory. Methodology and Results: The solid waste is previously characterized in the analysis phase. The contaminants are already known and they are insignificant due to their fast half- life. The iridium-192 half-life is 74.2 days, classified as very short half-life waste. The waste activity is adds to 8mCi (2.96x108 Bq) per wire. According to the CNEN-NN 6.08 standard, that presents the discharge levels, the limit is 1 kBq.kg-1 (2.7x10-5 mCi.kg-1). The radioactive waste generated during the I192 wires production has a weakly activity of 9.7 GBq.g-1. According to the standards, this activity is too high to be discarded into the environment. The waste must be managed following the ALARA principal using the R&R (retain e retard) system, that means, temporary storage and posterior discharge. Since every 4 months, maintenance is performed inside the hot cell used for production, the waste must be removed. Using the equation: 𝐴 = 𝐿 λ (1 − 𝑒−λt), the total calculated activity is 1.68 x 1016 Bq and 4.8 g mass at the end of each 4 months period. This amount is stored inside a shielding device that has 212.37 cm3 volume. The waste will take 9.8 years (calculated by 𝐴 = 𝐴0(𝑒−λt)) to decay to the discharge levels. To store 30 devices during 10 years, a space with 6,370 cm3 is necessary. The laboratory has enough space for this storage. Thus, the radioactive waste management can be performed through the R&R (retain and retard) system safely.
New methodology for binding Iodine-125 onto silver for brachytherapy sources manufacture
2017 - SOUZA, C.D. de; ROSTELATO, M.C.M.; CARDOSO, R.M.; ARAKI, K.; MOURA, J.
Purpose: Cancer is a major health care problem in Brazil and the world. The Brazil’s National Institute for Cancer estimates around 60,000 new prostate cancer cases for 2017. We are assembling a laboratory for production of iodine-125 sources used in prostate brachytherapy in Brazil, since the imported treatment is extremely expensive, thus only available in the private healthcare sector. There are several challenges when developing a laboratory to produce radioactive sources. From choosing a prototype to radiation safety, the task is enormous. The whole production line is full of new process and innovations. Among those, a new chemical reaction that deposit iodine-125 onto silver (core) was developed. This paper presents a new reaction for binding iodine-125 into a silver core. The fixation percentage was calculated by measuring the activity in an ionization chamber. This methodology will be implemented at the iodine-125 sources manufacture laboratory. Methods: Silver cores are washed with an etching solution (100% sulfuric acid) for 5 minutes with sonication. The cores were then placed in sodium sulfate for at least 3 days. They went from a silver matte to a black color. The reaction was allowed to proceed overnight. Each core was individually measured. Results: The yield was 69.2% 7.1%. Considering the silver attenuation is around 20% the results were consider satisfactory. Conclusion: By maximize the reaction yield, we will be able to generate a less costly product that will be available through our public healthcare.
New core configuration for producing Iodine 125 seeds
2017 - RODRIGUES, B.T.; ROSTELATO, M.C.M.; SOUZA, C.D. de; ZEITUNI, C.; MOURA, E.S. de; SOUZA, D.B. de; TOZETTI, C.; RODRIGUES, B.
Purpose: Cancer is one of the most complex public health problems. Prostate cancer is the second most common among men. In prostate brachytherapy use Iodine-125, which is fixated on a silver substrate, then inserted and sealed in a titanium capsule. This work proposes a new source configuration using epoxy resin substrate. Methods: Comparation and analysis methods were used to define the methodology for combining iodine-125 in polymers. The parameters were immersion time, reaction type, concentration of the adsorption solution, specific activity of the radioactive solution, need for carrier and chemical form of radioactive iodine. Results: The methodology developed with an epoxy resin was very good. The final radioactive intake on the resin was higher than 80%. The immobilization of the radioactive solution occurred in the matrix, without any loss or deposition of undesirable materials on its surface, as evidenced by the smear test. The material maintains its integrity when autoclaved at 140 °C. The curing process of the resin was 40 minutes. With the value of the initial activity of the Iodine solution by mass (774.2 lCi/g), it was possible to calculate the immobilization efficiency Average of 680 lCi/g. The immersion test in distilled water at room temperature did not exceed the limit allowed by ISO 9978, which is 5 nCi (185 Bq), proof of no leakage. In a computational simulation by the Monte Carlo Method, PENELOPE, the simulations were consistent with the values adopted by the literature for the GE Healthcare model 6711, which shows the value of the dose rate constant as 0, 965 cGy.U-1.h-1. Conclusion: The effective method for combining iodine-125 in epoxy resin was determinated. The major advantage was the high efficiency percentage fixation, around 82,1 3,2%, and the simplicity and safety of the process.
Methodology for in vivo dosimetry using TLD-100 for radiotherapic treatment
2017 - RODRIGUES, B.T.; SOUZA, P.D. de; SOUZA, C.D. de; ROSTELATO, M.C.M.; ZEITUNI, C.; NOGUEIRA, B.R.; MARQUES, J. de O.; SOUZA, A.S. de
Cancer is a public health problem that affects approximately 27 million people worldwide. The most common type in Brazil among men is prostate cancer with 61 thousand cases. There are two forms of radiotherapy treatments that can be used: teletherapy and brachytherapy. Before starting the teletherapy treatment, a planning is done that makes the acquisition of the anatomical information of the patient to then classify the areas of interest. Dosimetry is performed as a quality control to ensure that the calculated dose is equal to that received by the patient. In vivo dosimetry acts as an independent measurement and this work aims at comparing the dosimetry performed using thermoluminescent dosimeters (LiF: Mg, Ti - TLD - 100) with dose values calculated in the planning system (TPS). Methods: All dosimeters were prepared to be used in an anthropomorphic phantom. A selection of dosimeters, 50 micro TLD’s, selected after heat treatment, were then irradiated and a reading was made. A case planned by TPS was selected and compared the dosimetry performed in an anthropomorphic phantom for the same case. Results: All values obtained were within the deviation ( 5%) allowed by the protocol. The results of this work will help to implement a new quality program in the Radiotherapy Service at Hospital das Cl ınicas de S~ao Paulo. Conclusion: The accurate dosimeter selection provided a feasible and reliable evaluation that enabled the comparison.
Measurement of Iodine-125 radioactive solid waste derived from sources production laboratory for brachytherapy
2017 - SOUZA, D.B. de; ROSTELATO, M.C.M.; VICENTE, R.; ZEITUNI, C.; SOUZA, C.D. de; RODRIGUES, B.T.; MARQUES, J. de O.; CARVALHO, V.; BARBOSA, N.
Purpose: This study aims to present a solid waste management plan for the laboratory of radioactive sources production (LPFR), iodine-125 brachytherapy seeds, located at the Energy and Nuclear Research Institute (IPEN). After the implementation, it is expected to meet a demand of 8000 seeds per month. Methods: Waste from the production of Iodine-125 sources is classified as “Very Low Level Waste Disposal” (T1/2 ≤ 100 days) in the IAEA regulations. Despite that, they have levels of activity above the limits established in standard (CNEN 8.01) needing adequate management in order to guarantee the safety of the installation, operators and environment. The solid waste is generated in Glove box 1, were the fixation reaction (iodine-125 – core) takes place. The wastes from this production are absorbent papers and filters used in surface and air decontamination processes; glass vials, syringes and needles, used in the fixation reaction. Measures of mass, volume and values of activities generated over 5 years of production were performed for each glove box by estimating different scenarios throughout production (supplier switching, variation in activity by radioactive source, etc.). The concentration of activity was also determined in order to meet the criteria established in the standard for safe release of the waste. Results: The final volumes and activities calculated indicated that the laboratory has enough space for temporary storage until the release to the environment (thus not requiring treatment, transport, and another place for management). The data collected proved that a secure management system for radioactive waste within the facility is possible. Conclusion: The management proposed by this work was able to safely contemplate all stages of waste management. This data is indispensable for the construction and licensing of the laboratory.
Efficiancy of hydrogen peroxide for cleaning production areas and equipments in the Laboratory for Brachyterapy Sources Production
2017 - BAPTISTA, T.; ROSTELATO, M.C.M.; ZEITUNI, C.; PERINI, E.A.; SOUZA, C.D. de; MARQUES, J. de O.; NOGUEIRA, B.R.; ANGELOCCI, L.V.
Purpose: A great challenge in the brachytherapy sources production is to fulfill the Good Manufacturing Practices (GMPs) requirements, involving the process validation and of all supporting activities such as cleaning and sanitization. The increasingly strict requirements for quality assurance system, with several norms, normative resolutions and rules that must follow both medical products and radiochemical requirements, has led to a constant validation concerns. The main goal of GMP is to reduce inherent risks such as product contamination with microorganisms and cross-contamination. Methods: In the Laboratory for Brachytherapy Sources Production it was established a cleaning program for cleanrooms and hot cells using a hydrogen peroxide solution (6%). This work aims to assess the effectiveness of this cleaning agent in reducing and/or eliminating microbial load into the cleanrooms and equipments to acceptable levels in accordance with the current legislation. Results: The analysis was conducted using the results of the environmental monitoring program with settling contact plates in cleanrooms after the cleaning procedures. Furthermore, it was possible to evaluate the action of the sanitizing agent on the microbial population at the equipment and cleanrooms’ surfaces. It was also evaluated the best way to accomplish the cleaning program considering the dosimetry factor in each production process, hence the importance of radiological contamination. All the following environmental monitoring procedures presented satisfactory results, showing that the cleaning procedures was able to reduce and maintain the acceptable levels of viable and non-viable particles for the cleanroom classification (ISO 5 and ISO 7). The cleaning process with this sanitizer (hydrogen peroxide) can be performed quickly right before the production; allowing the production of brachytherapy sources without after use residues. Conclusion: This data will help the production of a clean and reliable product.